PMID- 35451909
OWN - NLM
STAT- MEDLINE
DCOM- 20221219
LR  - 20221222
IS  - 1744-764X (Electronic)
IS  - 1474-0338 (Linking)
VI  - 21
IP  - 11
DP  - 2022 Nov
TI  - Real-world practice patterns and characteristics of adverse events with selexipag 
      in Korean patients with pulmonary arterial hypertension.
PG  - 1423-1432
LID - 10.1080/14740338.2022.2069750 [doi]
AB  - BACKGROUND: Optimizing an individual dose with careful management of adverse 
      events (AEs) is essential in the treatment with selexipag approved for pulmonary 
      arterial hypertension (PAH). This study aims to identify real-world practice 
      patterns and AE characteristics of selexipag. RESEARCH DESIGN AND METHODS: This 
      multicenter, longitudinal, observational study included Korean patients with PAH 
      who initiated with selexipag and were followed up to 24 weeks. The dose-titration 
      pattern, AE incidences by dosing and time course, recovery pattern from AEs, and 
      relationship between doses and AE incidences were evaluated. RESULTS: Data for 
      113 patients were included in the analysis. The individual maintenance dose 
      ranged between 200 and 3,200 microg/day. More often AEs were occurred in the 
      titration phase than maintenance phase. There was no significant difference in AE 
      incidences according to the distribution of titration and maintenance doses. The 
      four most common AEs were diarrhea, headache, nausea/vomiting, and myalgia 
      without showing a dose-dependent trend in either frequency or severity. The 
      recovery rates were between 65.0% and 76.9% with a median time to recovery of 
      15-70 days (range, 2-233). CONCLUSION: Our finding that AE incidence did not 
      increase with increasing dose of selexipag would provide supportive real-world 
      evidence on the management of optimal dose and safety.
FAU - Chang, Sung-A
AU  - Chang SA
AD  - Division of Cardiology, Department of Medicine, Heart Vascular and Stroke 
      Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, 
      Seoul, Republic of Korea.
FAU - Lee, Sang Hyun
AU  - Lee SH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Yangsan Hospital, Pusan, Republic of Korea.
FAU - Choi, Jung Hyun
AU  - Choi JH
AD  - Division of Cardiology, Department of Internal Medicine, Pusan National 
      University Hospital, Pusan, Republic of Korea.
FAU - Chung, Wook-Jin
AU  - Chung WJ
AD  - Division of Cardiology, Department of Medicine, Gachon University Gil Medical 
      Center, Incheon, Republic of Korea.
FAU - Choi, Jae Young
AU  - Choi JY
AD  - Division of Pediatric Cardiology, Congenital Heart Disease Center, Severance 
      Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Republic 
      of Korea.
FAU - Kim, Hyung-Kwan
AU  - Kim HK
AD  - Division of Cardiology, Department of Internal Medicine Seoul National University 
      College of Medicine, Section of Cardiovascular Imaging, Cardiovascular Center, 
      Seoul National University Hospital, Seoul, Republic of Korea.
FAU - Jung, Hae-Ok
AU  - Jung HO
AD  - Division of Cardiology, Department of Medicine, The Catholic University of Korea 
      Seoul St. Mary's Hospital, Seoul, Republic of Korea.
FAU - Park, Seong-Mi
AU  - Park SM
AD  - Division of Cardiology, Korea University Medicine, Anam hospital, Seoul, Republic 
      of Korea.
FAU - Kim, Won-Jang
AU  - Kim WJ
AD  - Division of Cardiology, Department of Cardiology, CHA Bundang Medical Center, CHA 
      University School of Medicine, Republic of Korea.
FAU - Jung, Su Young
AU  - Jung SY
AD  - Medical Affairs, Janssen Korea Ltd, Seoul, Republic of Korea.
FAU - Chang, Hyuk-Jae
AU  - Chang HJ
AUID- ORCID: 0000-0002-6139-7545
AD  - Division of Cardiology, Severance Cardiovascular Hospital, Yonsei College of 
      Medicine, Seoul, Republic of Korea.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20220428
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 5EXC0E384L (selexipag)
RN  - 0 (Acetamides)
RN  - 0 (Antihypertensive Agents)
SB  - IM
MH  - Humans
MH  - *Pulmonary Arterial Hypertension/chemically induced/drug therapy
MH  - *Hypertension, Pulmonary/drug therapy
MH  - Acetamides
MH  - Republic of Korea/epidemiology
MH  - Antihypertensive Agents
OTO - NOTNLM
OT  - Adverse events
OT  - prescription pattern
OT  - pulmonary arterial hypertension
OT  - real-world
OT  - selexipag
EDAT- 2022/04/23 06:00
MHDA- 2022/12/20 06:00
CRDT- 2022/04/22 12:12
PHST- 2022/04/23 06:00 [pubmed]
PHST- 2022/12/20 06:00 [medline]
PHST- 2022/04/22 12:12 [entrez]
AID - 10.1080/14740338.2022.2069750 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2022 Nov;21(11):1423-1432. doi: 
      10.1080/14740338.2022.2069750. Epub 2022 Apr 28.